Skip to main content
. 2020 Jan 27;4(1):e336. doi: 10.1097/HS9.0000000000000336

Table 2.

Second-line Therapies; Antibody Alone Subsumes Rituximab, Alemtuzumab, Obinutuzumab, Ofatumumab; Ibrutinib or Idelalisib Subsume Ibrutinib, BRI vs BR + Placebo, CLL2BIG Study, Idelalisib and Idelalisib + Rituximab; Lenalidomide Subsumes Lenalidomide and BRL

graphic file with name hs9-4-e336-g008.jpg